サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：バイオシミラーの市場規模、シェア、動向分析：製品別、用途別、地域別、セグメント別予測2023年～2030年
市場調査レポート
商品コード
1321333

バイオシミラーの市場規模、シェア、動向分析：製品別、用途別、地域別、セグメント別予測2023年～2030年

Biosimilars Market Size, Share & Trends Analysis By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins), By Application (Rheumatoid Arthritis, Oncology), By Region And Segment Forecasts 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 70 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
バイオシミラーの市場規模、シェア、動向分析：製品別、用途別、地域別、セグメント別予測2023年～2030年
出版日: 2023年07月04日
発行: Grand View Research
ページ情報: 英文 70 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオシミラー市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のバイオシミラー市場規模は2023年から2030年にかけて15.9%のCAGRを記録し、2030年には762億米ドルに達すると予測されています。

同市場の成長は、患者・メーカー双方にとって費用対効果が高いこと、がんや貧血などの慢性・非感染性疾患の有病率が増加していることに起因しています。世界保健機関（WHO）の推計によると、5歳未満の子どもの40％、15～49歳の女性の30％が貧血に苦しんでいます。さらに、バイオシミラー医薬品はほぼ同様の結果をもたらし、参照生物製剤よりも手頃な代替品と考えられています。

ほぼ同様であるため、生物学的製剤の生産者もバイオシミラーに対抗するために価格を下げざるを得ず、治療費全体が削減されます。例えば、バイオシミラーフォーラムが2021年4月に発表した報告書によると、バイオシミラーとの競合が激化した結果、生物学的製剤の価格は平均56％から最大150％引き下げられました。さらに、生物製剤にはバイオシミラーとの競合を防ぐための特許があります。これらの特許は、各国の規制によって8年から20年の期間、バイオシミラーの生産を制限します。しかし、多くの救命用生物製剤の特許は予測期間中に失効すると予想されており、これが成長を後押しする可能性があります。

2021年4月に発表された米国議会予算局の記事によると、米国食品医薬品局（FDA）は2020年までに29のバイオシミラー医薬品を承認しており、そのうちのいくつかはまだ市場に導入されていないです。さらに、ジェネリック医薬品・バイオシミラー・イニシアチブ（Generics and Biosimilars Initiative）の記事によると、アムジェン社のバイオシミラー「ソリリス」の市場導入は2025年まで延期されました。COVID-19パンデミックの発生は世界市場に悪影響を及ぼしました。医薬品を含むさまざまな製品のサプライチェーンが寸断され、供給元のほとんどがCOVID-19対策に専念したため、バイオシミラーの生産は原材料不足に陥っています。

例えば、ジョンズ・ホプキンス大学ブルームバーグ公衆衛生大学院が発表した報告書によると、封鎖の結果、医薬品の製造に使用される重要な原材料である原薬（API）の供給不足が観察されました。こうした供給不足は、パンデミックの間、バイオシミラーやその他の医薬品の生産と供給に直接影響を与えました。しかし、需要の増加により、複数の市場プレーヤーがバイオシミラーの研究開発に多額の投資を行っており、これが市場の成長をさらに押し上げる可能性があります。例えば、高度なバイオテクノロジー・ソリューションを提供する主なプレーヤーであるAmgen Inc.は、10のバイオシミラー医薬品の開発に20億米ドルを投資しています。

バイオシミラー市場レポートハイライト

  • 製品別では、遺伝子組換え非グリコシル化タンパク質分野が、2022年に54.9%の最大売上シェアを占めました。
  • 一方、遺伝子組換え糖鎖タンパク質セグメントは、複数の救命用生物製剤の特許が間もなく失効すると予想されるため、予測期間中に14.9%のCAGRで最速の成長が見込まれています。
  • 慢性疾患および自己免疫疾患への応用分野は、これらの疾患の有病率が上昇していることから、2022年に最大の売上シェアを占めました。
  • がん領域は、がん罹患率の増加と重要な生物製剤の特許切れが近いことから、予測期間中に17.0%のCAGRを記録する見込みです。
  • 2022年には、複数の主要企業が存在する北米が40.4%のシェアを占め、市場を独占しました。一方、アジア太平洋地域は、新製品の上市とヘルスケア支出の増加により、予測期間中にCAGR 18.4%で最も急成長する地域と予測されます。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 調査手法
  • 情報調達
  • 情報またはデータ分析
  • 市場の形成と検証
  • モデル詳細
  • 二次情報のリスト
  • 一次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

第3章 バイオシミラー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 業界のバリューチェーン分析
    • 償還の枠組み
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • バイオシミラー市場分析ツール
    • 業界分析- ポーターズ
    • PESTEL分析

第4章 バイオシミラー市場：製品推定・動向分析

  • バイオシミラー市場：重要なポイント
  • バイオシミラー市場：動向と市場シェア分析、2022年および2030年
  • 組換え非グリコシル化タンパク質
    • 組換え非グリコシル化タンパク質市場推計・予測、2018年から2030年まで
    • ヒト成長ホルモン
    • 顆粒球コロニー刺激因子
    • インターフェロン
    • インスリン
  • 組換えグリコシル化タンパク質
    • 組換えグリコシル化タンパク質市場推計・予測、2018年から2030年まで
    • エリスロポエチン
    • モノクローナル抗体
    • フォリトロピン

第5章 バイオシミラー市場：用途推定・動向分析

  • バイオシミラー市場：重要なポイント
  • バイオシミラー市場：動向と市場シェア分析、2022年および2030年
  • 腫瘍学
  • 血液疾患
  • 成長ホルモン欠乏症
  • 慢性および自己免疫疾患
  • その他

第6章 バイオシミラー市場：地域推定・動向分析

  • 地域別の見通し
  • 地域別バイオシミラー市場：主要なマーケットプレース要点
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Amgen Inc.
    • F Hoffman La Roche Ltd.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co., Ltd
    • AbbVie Inc.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 3 North America biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 4 North America biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 5 U.S. biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 6 U.S. biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 7 Canada biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 8 Canada biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 9 Europe biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 10 Europe biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 11 Europe biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 12 Germany biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Germany biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 14 UK biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 15 UK biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 16 France biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 17 France biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 18 Italy biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 19 Italy biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 20 Spain biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 21 Spain biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 22 Sweden biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 23 Sweden biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Norway biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 25 Norway biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 26 Denmark biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Denmark biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 31 China biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 32 China biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 33 Japan biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 34 Japan biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 35 India biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 36 India biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 37 Thailand biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 38 Thailand biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 39 South Korea biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 40 South Korea biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 41 Latin America biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 42 Latin America biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 43 Latin America biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 44 Brazil biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 45 Brazil biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 46 Mexico biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 47 Mexico biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 48 Argentina biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 49 Argentina biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 50 Middle East and Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 51 Middle East and Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 52 Middle East and Africa biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 53 South Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 54 South Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 55 Saudi Arabia biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 56 Saudi Arabia biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 57 UAE biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 58 UAE biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 59 Kuwait biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 60 Kuwait biosimilars market, by application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Biosimilars market outlook
  • Fig. 9 Biosimilars competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Biosimilars market driver impact
  • Fig. 15 Biosimilars market restraint impact
  • Fig. 16 Biosimilars market strategic initiatives analysis
  • Fig. 17 Biosimilars market: Product movement analysis
  • Fig. 18 Biosimilars market: Product outlook and key takeaways
  • Fig. 19 Recombinant non-glycosylated proteins market estimates and forecasts, 2018 - 2030
  • Fig. 20 Recombinant glycosylated proteins market estimates and forecasts, 2018 - 2030
  • Fig. 21 Biosimilars market: Application movement analysis
  • Fig. 22 Biosimilars market: Application outlook and key takeaways
  • Fig. 23 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 24 Blood disorders market estimates and forecasts, 2018 - 2030
  • Fig. 25 Growth hormonal deficiency market estimates and forecasts, 2018 - 2030
  • Fig. 26 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030
  • Fig. 27 Chronic and autoimmune disorders market estimates and forecasts, 2018 - 2030
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030
  • Fig. 29 Global biosimilars market: Regional movement analysis
  • Fig. 30 Global biosimilars market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 34 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 37 France market estimates and forecasts, 2018 - 2030
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 45 China market estimates and forecasts, 2018 - 2030
  • Fig. 46 India market estimates and forecasts, 2018 - 2030
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: 978-1-68038-916-6

Biosimilars Market Growth & Trends

The global biosimilars market size is expected to reach USD 76.2 billion by 2030, registering a CAGR of 15.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of this market can be attributed to their cost effectiveness for both patients & manufacturers and the increasing prevalence of chronic & non-communicable diseases, such as cancer and anemia. According to the World Health Organizationestimates, 40% of children below five years of age, and 30% of women between the age group of 15 and 49 years are suffering from anemia. Moreover, biosimilar drugs offer almost similar results and are considered a more affordable alternative to their reference biologics.

Since they are almost similar, the producers of biologics also have to lower their prices to compete with biosimilars, which reduce the cost of the overall treatment. For instance, a report published by Biosimilars Forum in April 2021 suggests that increasing competition from biosimilars has resulted in lowering the prices of biologics by an average of 56% to up to 150%. Furthermore, biologics have patents to protect them from competing with biosimilars. These patents restrict the production of biosimilars for a period of 8 to 20 years depending on the regulations in different countries. However, patents of many lifesaving biologics are expected to expire during the forecast period, which can boost growth.

According to an article by Congressional Budget Office published in April 2021, the U.S. Food and Drugs Administration (FDA) had approved 29 biosimilar drugs by 2020, and some of them were yet to be introduced in the market. Furthermore, an article by Generics and Biosimilars Initiative suggests, the entry of Amgen's biosimilar Soliris was delayed till 2025. The outbreak of the COVID-19 pandemic had a negative impact on the global market. Since the supply chains of different products including pharmaceuticals were disrupted and most of the sources were dedicated to fighting COVID-19, the production of biosimilars experienced a shortage of raw materials.

For instance, according to a report published by Johns Hopkins Bloomberg School of Public Health, as a result of the lockdown, a shortage was observed in the supply of Active Pharmaceutical Ingredient (API), which is an important raw material used in producing drugs. These shortages directly affected the production and supply of biosimilars and other drugs during the pandemic. However, due to the increasing demand, several market players are significantly investing in the research & development of biosimilars, which can further add to the market growth. For instance, a key player offering advanced biotechnology solutions, Amgen Inc., has invested USD 2 billion in the development of 10 biosimilar medicines.

Biosimilars Market Report Highlights

  • Based on product, the recombinant non-glycosylated proteins segment accounted for the largest revenue share of 54.9% in 2022 due to a rise in the regulatory approvals for biosimilars from different governments
  • On the other hand, the recombinant glycosylated proteins segment is expected to grow at the fastest CAGR of 14.9% during the forecast period as the patents of several lifesaving biologics are expected to expire soon
  • The chronic and autoimmune disorders application segment accounted for the largest revenue share in 2022owing to the rising prevalence of these diseases
  • The oncology segment is expected to register the fastest CAGR of 17.0% during the forecast period due to the increasing prevalence of cancer and upcoming patent expiration for important biologics
  • In 2022, North America dominated the market with a share of 40.4% owing to the presence of several key players. On the other hand, Asia Pacific is anticipated to be the fastest-growing region at a CAGR of 18.4% over the forecast period due to new product launches and increasing healthcare expenditure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biosimilars Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing emphasis on cutting down healthcare expenditure
      • 3.4.1.2. Cost-effectiveness of biosimilar drugs
      • 3.4.1.3. Positive outcome in the ongoing clinical trials
      • 3.4.1.4. R&D investments are increasing.
      • 3.4.1.5. Patent expiration of biologics to boost the biosimilars market
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. High manufacturing complexities and costs
      • 3.4.2.2. Presence of non-original biologics and biobetters
  • 3.5. Biosimilars Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Biosimilars Market: Product Estimates & Trend Analysis

  • 4.1. Biosimilars Market: Key Takeaways
  • 4.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Recombinant Non-glycosylated Proteins
    • 4.3.1. Recombinant non-glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Human growth hormone
      • 4.3.2.1. Human growth hormone market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3. Granulocyte colony-stimulating factor
      • 4.3.3.1. Granulocyte colony-stimulating factor market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.4. Interferons
      • 4.3.4.1. Interferons market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.5. Insulin
      • 4.3.5.1. Insulin market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Recombinant Glycosylated Proteins
    • 4.4.1. Recombinant glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2. Erythropoietin
      • 4.4.2.1. Erythropoietin market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3. Monoclonal antibodies
      • 4.4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.4. Follitropin
      • 4.4.4.1. Follitropin market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Biosimilars Market: Application Estimates & Trend Analysis

  • 5.1. Biosimilars Market: Key Takeaways
  • 5.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Oncology
    • 5.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.4. Blood Disorders
    • 5.4.1. Blood disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.5. Growth Hormonal Deficiency
    • 5.5.1. Growth hormonal deficiency market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.6. Chronic And Autoimmune Disorders
    • 5.6.1. Chronic and autoimmune disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Biosimilars Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Biosimilars Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Amgen Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. F Hoffman La Roche Ltd.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Sandoz International GmbH
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Dr. Reddy's Laboratories Ltd.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Teva Pharmaceutical Industries Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Pfizer Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Samsung Biopis
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Biocon
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Viatris Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Celltrion Healthcare Co., Ltd
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. AbbVie Inc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives